Vanda Pharmaceuticals Inc. (VNDA) Earnings
Vanda Pharmaceuticals Inc. is expected to report next earnings on July 30, 2026 (in NaN days), with a consensus EPS estimate of $-0.60. VNDA has beaten EPS estimates in 7 of its last 11 reported quarters (average surprise -30.6% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $-0.53 | $-0.82 | -54.7% | $52M | -5.9% |
| Feb 11, 2026 | $-2.18 | $-2.39 | -9.6% | $57M | -7.4% |
| Oct 29, 2025 | $-0.31 | $-0.38 | -22.6% | $56M | -5.1% |
| Jul 31, 2025 | $-0.34 | $-0.46 | -35.3% | $53M | -10.5% |
| May 7, 2025 | $-0.55 | $-0.50 | +9.1% | $50M | +10.9% |
| Feb 13, 2025 | $-0.14 | $-0.08 | +42.9% | $53M | +1.8% |
| Jul 31, 2024 | $-0.21 | $-0.08 | +61.9% | $50M | -0.5% |
| Feb 7, 2024 | $-0.09 | $-0.04 | +55.6% | $45M | +22.4% |
| Nov 8, 2023 | $0.00 | $0.00 | +100.0% | $39M | -12.8% |
| Jul 27, 2023 | $-0.13 | $0.03 | +123.1% | $46M | -8.8% |
| May 3, 2023 | — | $0.06 | — | $62M | — |
| Feb 8, 2023 | $0.08 | $0.12 | +50.0% | $64M | -4.6% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
CEO mentioned strong commercial execution in Q1 2026, including 26% YOY growth in FNAF sales, launch of Nereus, and FDA approval of Bisanti. CFO summarized financial results, with total revenues at $51.7 million, and detailed breakdowns by product segments, operating expenses, and cash position.
Guidance
Vanda raises full-year 2026 revenue guidance to $240-$290 million, including $10-$30 million from newly launched Nereus. FNAP net product sales expected to be between $150 and $170 million. Other net product sales between $80 and $90 million. Nereus net product sales between $10 and $30 million.
Segment performance
FNAP net product sales were $29.6 million in Q1 2026, a 26% year-over-year increase. Hetlios net product sales were $15.9 million, a 24% decrease year-over-year. Ponvory net product sales were $6.2 million, a 10% increase year-over-year. Total net product sales reached $51.7 million in Q1 2026, a 3% increase from Q1 2025.
Risks & headwinds
Risks include forward-looking statement risks, revenue fluctuations due to market competition, uncertainties in product launches, and risks related to pipeline study progress.
Analyst Q&A
Q: Run through what the pushes and pulls are for Nereus' 10-30 million guidance range and Bisanti's launch progress.
A: It's early for Nereus launch, range based on market modeling. Bisanti launch on track in back half of 2026.
Q: Color on Tredipitant study timeline and expectations.
A: Results by end of 2026, similar design to Phase 2 with positive results.